COVID-19 in Pediatric Populations
COVID-19 in Pediatric Populations

COVID-19 in Pediatric Populations

Clin Chest Med. 2024 Sep;45(3):675-684. doi: 10.1016/j.ccm.2024.02.019.

ABSTRACT

The COVID-19 pandemic reshaped the landscape of respiratory viral illnesses, causing common viruses to fade as SARS-CoV-2 took precedence. By 2023, more than 96% of the children in the United States were estimated to have been infected with SARS-CoV-2, with certain genetic predispositions and underlying health conditions posing risk factors for severe disease in children. Children, in general though, exhibit immunity advantages, protecting against aspects of the SARS-CoV-2 infection known to drive increased severity in older adults. Post-COVID-19 complications such as multisystem inflammatory syndrome in children and long COVID have emerged, underscoring the importance of vaccination. Here, we highlight the risks of severe pediatric COVID-19, age-specific immunoprotection, comparisons of SARS-CoV-2 with other respiratory viruses, and factors contributing to post-COVID-19 complications in children.

PMID:39069330 | DOI:10.1016/j.ccm.2024.02.019